Vertex Pharmaceuticals VRTX
-
Cramer's Lightning Round - Titan Is In-Your-Face Optimistic (5/23/12)
… I share their optimism. They were toughly optimistic. They were in-your-face optimistic. But I do like it." Vertex ( VRTX ), Celgene ( CELG ): "I think (Vertex) goes remarkably higher. It has done lots of back and forth. It could go to $80 …
-
Chelsea: A Short-Term Buying Opportunity
By Kevin CC : On May 22, 2012, management at Chelsea Therapeutics ( CHTP ) held a conference call to inform investors about the results of the End-of-Review meeting the company had with the U.S. Food and Drug Administration (FDA). In March the FDA issued CHTP a complete response letter (CRL) ...
-
Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Sells
By Ganaxi Small Cap Movers : trades. Complete Story »
-
Biotech Sector Avoids Nasty Correction And Hits New Highs
… Trust Arca Biotechnology Index Fund is up 38% YTD riding some big winners like Amylin ( AMLN ) Regeneron ( REGN ) and Vertex ( VRTX ). Recently Benziga published an article on biotech ETF's reiterating the underlying basis for strength in the sector: M …
-
Redefining The Meaning Of 'Creating Shareholder Value' In Biotech
By Prohost Biotech : The time has come for redefining the meaning of “creating shareholder value” in the biotech sector. Pinpointing the real value has become imperative. It is the road to a fair assessment of innovative biotech firms. It helps investors reap the fruits of the real value of ...
-
Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's ( VRTX ) cystic fibrosis treatment - and because some investors are betting on deals ...
Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's ( VRTX ) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly …
-
New Morningstar Analyst Report - WuXi PharmaTech (Cayman), Inc.
… manufacturing segment has been a huge growth driver in recent quarters. WuXi provides production capabilities for Vertex's VRTX hepatitis C drug Incivek, which is experiencing one of the strongest launches in drug history and is already earning blockbuster …
-
New Morningstar Analyst Report - Gilead Sciences
… in a strong position to compete with (and potentially displace) novel, effective hepatitis C therapies including Vertex's VRTX Incivek and Merck's Victrelis. While Gilead is currently reliant on the molecule in Viread for its profitability, approval …
-
Vertex's Cystic Fibrosis Drug Impresses Investors
By The Burrill Report : By Vinay Singh Vertex Pharmaceuticals ( VRTX ) saw its shares soar after it released interim mid-stage data on a combination drug that exceeded the company's expectations …
-
Idenix Will Move Up On Promising New Data In 2013
By Vatalyst : With so many pharmaceutical companies developing and testing new Hepatitis C drug treatments lately, investors may find it difficult to keep up. Idenix Pharmaceuticals ( IDIX ) recently revealed some promising news concerning clinical trials for one of its new Hepatitis C drug ...